JP2011529858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529858A5 JP2011529858A5 JP2011520297A JP2011520297A JP2011529858A5 JP 2011529858 A5 JP2011529858 A5 JP 2011529858A5 JP 2011520297 A JP2011520297 A JP 2011520297A JP 2011520297 A JP2011520297 A JP 2011520297A JP 2011529858 A5 JP2011529858 A5 JP 2011529858A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- pharmaceutically acceptable
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 90
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 43
- 230000002452 interceptive effect Effects 0.000 claims description 41
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 230000004770 neurodegeneration Effects 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 206010020751 Hypersensitivity Diseases 0.000 claims description 15
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 15
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 14
- 208000034799 Tauopathies Diseases 0.000 claims description 14
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 14
- 206010012289 Dementia Diseases 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 13
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 12
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 11
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 9
- 206010034010 Parkinsonism Diseases 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 230000009610 hypersensitivity Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 7
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004072 lung Anatomy 0.000 claims description 7
- 230000000750 progressive effect Effects 0.000 claims description 7
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 208000020446 Cardiac disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 230000035939 shock Effects 0.000 claims description 5
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 4
- 208000017227 ADan amyloidosis Diseases 0.000 claims description 4
- 206010058284 Allergy to arthropod sting Diseases 0.000 claims description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 4
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 4
- 206010018341 Gliosis Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 208000032843 Hemorrhage Diseases 0.000 claims description 4
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 4
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 4
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 4
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000024777 Prion disease Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 229940124639 Selective inhibitor Drugs 0.000 claims description 4
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 4
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims description 4
- 208000034158 bleeding Diseases 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 201000005311 drug allergy Diseases 0.000 claims description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 230000007387 gliosis Effects 0.000 claims description 4
- 208000024908 graft versus host disease Diseases 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 206010023497 kuru Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000005987 polymyositis Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 4
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 4
- 208000004434 Calcinosis Diseases 0.000 claims description 3
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 210000004227 basal ganglia Anatomy 0.000 claims description 3
- 230000002308 calcification Effects 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 201000006061 fatal familial insomnia Diseases 0.000 claims description 3
- 230000020764 fibrinolysis Effects 0.000 claims description 3
- 210000001905 globus pallidus Anatomy 0.000 claims description 3
- 208000021822 hypotensive Diseases 0.000 claims description 3
- 230000001077 hypotensive effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 206010024715 Liver transplant rejection Diseases 0.000 claims description 2
- 206010051604 Lung transplant rejection Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims description 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 208000035802 chromosome 17 disease Diseases 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 208000018639 Parkinson disease 20 Diseases 0.000 claims 1
- 241000232971 Passer domesticus Species 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 20
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 230000006951 hyperphosphorylation Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000024571 Pick disease Diseases 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229940124810 Alzheimer's drug Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001435 Synapsin Human genes 0.000 description 2
- 108050009621 Synapsin Proteins 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 208000009093 Diffuse Neurofibrillary Tangles with Calcification Diseases 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8553808P | 2008-08-01 | 2008-08-01 | |
| US61/085,538 | 2008-08-01 | ||
| PCT/CA2009/001088 WO2010012107A1 (en) | 2008-08-01 | 2009-07-31 | Selective glycosidase inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529858A JP2011529858A (ja) | 2011-12-15 |
| JP2011529858A5 true JP2011529858A5 (https=) | 2012-09-06 |
| JP5687194B2 JP5687194B2 (ja) | 2015-03-18 |
Family
ID=41609897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520297A Expired - Fee Related JP5687194B2 (ja) | 2008-08-01 | 2009-07-31 | 選択的グリコシダーゼインヒビターおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9079868B2 (https=) |
| EP (1) | EP2321289A4 (https=) |
| JP (1) | JP5687194B2 (https=) |
| AU (1) | AU2009276223B2 (https=) |
| CA (1) | CA2732336A1 (https=) |
| WO (1) | WO2010012107A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2599843C (en) * | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| AU2007291870B2 (en) | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| US8901087B2 (en) | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) * | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| WO2012159262A1 (en) * | 2011-05-24 | 2012-11-29 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2688899B1 (en) | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013033098B8 (pt) | 2011-06-27 | 2021-03-23 | Alectos Therapeutics Inc | inibidores de glicosidade seletivos e usos dos mesmos |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9126957B2 (en) * | 2011-08-18 | 2015-09-08 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| US9603907B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Dry powder formulations of dNase I |
| EP2847199B1 (en) | 2012-05-08 | 2017-10-25 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| US20160017020A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same |
| WO2019173506A1 (en) * | 2018-03-07 | 2019-09-12 | The Broad Institute, Inc. | Cyclopentaimidazolones for the treatment of cancer |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131672A (zh) * | 1994-11-22 | 1996-09-25 | 生化学工业株式会社 | 氨基环戊烷衍生物 |
| JPH11349541A (ja) * | 1998-06-08 | 1999-12-21 | Sankyo Co Ltd | アロサミゾリン誘導体の新規な中間体 |
| BR0211468A (pt) | 2001-07-24 | 2004-11-23 | Univ Yale | Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero |
| CA2599843C (en) * | 2005-03-01 | 2013-08-27 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| AU2007291870B2 (en) * | 2006-08-31 | 2012-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2113589A1 (en) * | 2008-04-29 | 2009-11-04 | Total Petrochemicals Research Feluy | Fibers and nonwovens with improved bonding properties |
| CA2732335A1 (en) * | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CA2737267A1 (en) * | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2011140640A1 (en) * | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| US8933040B2 (en) * | 2010-11-08 | 2015-01-13 | Craig A. Coburn | Selective glycosidase inhibitors and uses thereof |
| RU2609210C2 (ru) * | 2010-12-23 | 2017-01-31 | Алектос Терапьютикс Инк. | Селективные ингибиторы гликозидазы и их применение |
| EP2688899B1 (en) * | 2011-03-24 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) * | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| BR112013033098B8 (pt) | 2011-06-27 | 2021-03-23 | Alectos Therapeutics Inc | inibidores de glicosidade seletivos e usos dos mesmos |
| US9126957B2 (en) | 2011-08-18 | 2015-09-08 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| EP2847199B1 (en) | 2012-05-08 | 2017-10-25 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
| US9522883B2 (en) | 2012-08-31 | 2016-12-20 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890676B1 (en) | 2012-08-31 | 2018-12-05 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| EP2890679A4 (en) | 2012-08-31 | 2016-05-04 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| EP2890675A4 (en) | 2012-08-31 | 2016-01-13 | Alectos Therapeutics Inc | GLYCOSIDASE INHIBITORS AND USES THEREOF |
| KR20150079711A (ko) | 2012-10-31 | 2015-07-08 | 알렉토스 테라퓨틱스 인크. | 글리코시다아제 저해제 및 이의 용도 |
| WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
-
2009
- 2009-07-31 EP EP09802333A patent/EP2321289A4/en not_active Withdrawn
- 2009-07-31 JP JP2011520297A patent/JP5687194B2/ja not_active Expired - Fee Related
- 2009-07-31 AU AU2009276223A patent/AU2009276223B2/en not_active Ceased
- 2009-07-31 US US13/057,065 patent/US9079868B2/en not_active Expired - Fee Related
- 2009-07-31 WO PCT/CA2009/001088 patent/WO2010012107A1/en not_active Ceased
- 2009-07-31 CA CA2732336A patent/CA2732336A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529858A5 (https=) | ||
| JP2011529857A5 (https=) | ||
| JP6585266B2 (ja) | Ｈｓｐ９０の阻害による神経変性疾患の処置 | |
| CN103298460B (zh) | 酪蛋白激酶1δ(CK1δ)抑制剂 | |
| JP2012502884A5 (https=) | ||
| Chowdhury et al. | Phenotypic optimization of urea–thiophene carboxamides to yield potent, well tolerated, and orally active protective agents against aminoglycoside-induced hearing loss | |
| JP5687194B2 (ja) | 選択的グリコシダーゼインヒビターおよびその使用 | |
| JP6322177B2 (ja) | 選択的グルコシダーゼインヒビターおよびその使用 | |
| JP6243921B2 (ja) | Ｂａｃｅ阻害剤 | |
| EP3389658A1 (en) | Glycosidase inhibitors and uses thereof | |
| JP2014501740A5 (https=) | ||
| JP6067099B2 (ja) | テトラヒドロピロロチアジン化合物 | |
| WO2008025170B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| EA022649B1 (ru) | ПРОИЗВОДНЫЕ 6,7-ДИГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
| Hartz et al. | Design, structure–activity relationships, and in vivo evaluation of potent and brain-penetrant imidazo [1, 2-b] pyridazines as glycogen synthase kinase-3β (GSK-3β) inhibitors | |
| JP2012502884A (ja) | 選択的グリコシダーゼ阻害剤およびその使用 | |
| JP2015534991A5 (https=) | ||
| AU2016246098B2 (en) | Methods for selecting phosphatase selective and non-selective phosphatase inhibitors | |
| Huang et al. | Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity | |
| Hartz et al. | Discovery of 2-(anilino) pyrimidine-4-carboxamides as highly potent, selective, and orally active glycogen synthase kinase-3 (GSK-3) inhibitors | |
| JP7361179B2 (ja) | 併用療法 | |
| Bai et al. | Development and pharmacochemical characterization discover a novel brain-permeable HDAC11-selective inhibitor with therapeutic potential by regulating neuroinflammation in mice | |
| JP2024509936A (ja) | Ｕｓｐ３０阻害剤及びその使用 | |
| WO2007084162A2 (en) | Sirtuin inhibiting compounds | |
| Ganegamage et al. | 1, 4-Diurea-and 1, 4-Dithiourea-Substituted aromatic derivatives selectively inhibit α-Synuclein oligomer formation In vitro |